Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update
Stuart A. Scott,Katrin Sangkuhl,Charles M. Stein,Jean-Sébastien Hulot,Jean-Sébastien Hulot,Jessica L. Mega,Dan M. Roden,Teri E. Klein,Marc S. Sabatine,Julie A. Johnson,Julie A. Johnson,Alan R. Shuldiner,Alan R. Shuldiner +12 more
Reads0
Chats0
TLDR
In this article, an expanded literature review showed that CYP2C19 loss-of-function alleles confer increased risks for serious adverse cardiovascular (CV) events among clopidogrel-treated patients with acute coronary syndromes (ACSs) undergoing percutaneous coronary intervention (PCI).Abstract:
Cytochrome P450 (CYP)2C19 catalyzes the bioactivation of the antiplatelet prodrug clopidogrel, and CYP2C19 loss-of-function alleles impair formation of active metabolites, resulting in reduced platelet inhibition. In addition, CYP2C19 loss-of-function alleles confer increased risks for serious adverse cardiovascular (CV) events among clopidogrel-treated patients with acute coronary syndromes (ACSs) undergoing percutaneous coronary intervention (PCI). Guideline updates include emphasis on appropriate indication for CYP2C19 genotype–directed antiplatelet therapy, refined recommendations for specific CYP2C19 alleles, and additional evidence from an expanded literature review (updates at http://www.pharmgkb.org).read more
Citations
More filters
Journal ArticleDOI
Clinical pharmacogenetics implementation: Approaches, successes, and challenges
Kristin Weitzel,Amanda R. Elsey,Taimour Y. Langaee,Benjamin Burkley,David R. Nessl,Aniwaa Owusu Obeng,Benjamin Staley,Hui-Jia Dong,Robert W. Allan,J. Felix Liu,Rhonda M. Cooper-DeHoff,R. David Anderson,Michael Conlon,Michael J. Clare-Salzler,David R. Nelson,Julie A. Johnson +15 more
TL;DR: The processes for development of the UF PMP, the challenges that were encountered and the clinical acceptance by clinicians of the genomic medicine implementation are described are described.
Journal ArticleDOI
PharmVar GeneFocus: CYP2D6.
Zeruesenay Desta,Ahmed El-Boraie,Li Gong,Andrew A. Somogyi,Volker M. Lauschke,Collet Dandara,Kathrin Klein,Kathrin Klein,Neil A. Miller,Neil A. Miller,Teri E. Klein,Rachel F. Tyndale,Michelle Whirl-Carrillo,Andrea Gaedigk,Andrea Gaedigk +14 more
TL;DR: This GeneFocus provides a comprehensive overview and summary of CYP2D6 genetic variation and describes how the information provided by PharmVar is utilized by the Pharmacogenomics Knowledgebase (PharmGKB) and the Clinical Pharmacogenetics Implementation Consortium (CPIC).
Journal ArticleDOI
The Clinical Pharmacogenetics Implementation Consortium: 10 Years Later
Mary V. Relling,Teri E. Klein,Roseann S. Gammal,Roseann S. Gammal,Michelle Whirl-Carrillo,James M. Hoffman,Kelly E. Caudle +6 more
TL;DR: Since its inception, CPIC's interactions with other resources, databases, websites, and genomic communities have grown and the progress of CPIC over the past 10 years is highlighted.
Journal ArticleDOI
“East Asian Paradox”: Challenge for the Current Antiplatelet Strategy of “One-Guideline-Fits-All Races” in Acute Coronary Syndrome
TL;DR: In terms of antiplatelet therapy, recent evidence has supported the concept of "therapeutic level of platelet reactivity" to balance clinical efficacy and safety in patients undergoing percutaneous coronary intervention (PCI) or those with acute coronary syndrome (ACS).
Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention
Larisa H. Cavallari,Craig R. Lee,Amber L. Beitelshees,Rhonda M. Cooper-DeHoff,Julio D. Duarte,Deepak Voora,Stephen E. Kimmel,Caitrin W. McDonough,Yan Gong,Chintan V. Dave,Victoria M. Pratt,Tameka D. Alestock,R. David Anderson,Jorge A. Alsip,Amer Ardati,Brigitta C. Brott,Lawrence Brown,Supatat Chumnumwat,Michael J. Clare-Salzler,James C. Coons,Joshua C. Denny,Chrisly Dillon,Amanda R. Elsey,Issam Hamadeh,Shuko Harada,William B. Hillegass,Lindsay J. Hines,Richard B. Horenstein,Lucius A. Howell,Linda J. B. Jeng,Mark D. Kelemen,Yee Ming Lee,Oyunbileg Magvanjav,May E. Montasser,David R. Nelson,Edith A. Nutescu,Devon C. Nwaba,Ruth E. Pakyz,Kathleen Palmer,Josh F. Peterson,Toni I. Pollin,Alison H. Quinn,Shawn W. Robinson,Jamie Schub,Todd C. Skaar,Donald M. Smith,Vindhya B. Sriramoju,Petr Starostik,Tomasz Stys,James M. Stevenson,Nicholas Varunok,Mark R. Vesely,Dyson T. Wake,Karen E. Weck,Kristin Weitzel,Russell A. Wilke,James H. Willig,Richard Y. Zhao,Rolf P. Kreutz,George A. Stouffer,Philip E. Empey,Nita A. Limdi,Alan R. Shuldiner,Almut G. Winterstein,Julie A. Johnson +64 more
TL;DR: These data from real-world observations demonstrate a higher risk for cardiovascular events in patients with a CYP2C19 loss-of-function allele if clopidogrel versus alternative therapy is prescribed.
References
More filters
Journal ArticleDOI
Meta-Analysis: A Constantly Evolving Research Integration Tool
TL;DR: The four articles in this special section onMeta-analysis illustrate some of the complexities entailed in meta-analysis methods and contributes both to advancing this methodology and to the increasing complexities that can befuddle researchers.
Journal ArticleDOI
Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
Stephen D. Wiviott,Eugene Braunwald,Carolyn H. McCabe,Gilles Montalescot,Witold Rużyłło,Shmuel Gottlieb,Franz Joseph Neumann,Diego Ardissino,Stefano De Servi,Sabina A. Murphy,Jeffrey S. Riesmeyer,Govinda Weerakkody,C. Michael Gibson,Elliott M. Antman +13 more
TL;DR: In patients with acute coronary syndromes with scheduled percutaneous coronary intervention, prasugrel therapy was associated with significantly reduced rates of ischemic events, including stent thrombosis, but with an increased risk of major bleeding, including fatal bleeding.
Journal ArticleDOI
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
Lars Wallentin,Richard C. Becker,Andrzej Budaj,Christopher P. Cannon,Håkan Emanuelsson,Claes Held,Jay Horrow,Steen Husted,Stefan James,Hugo A. Katus,Kenneth W. Mahaffey,Benjamin M. Scirica,Allan M. Skene,Philippe Gabriel Steg,Robert F. Storey,Robert A. Harrington +15 more
TL;DR: In patients who have an acute coronary syndrome with or without ST-segment elevation, treatment with ticagrelor as compared with clopidogrel significantly reduced the rate of death from vascular causes, myocardial infarction, or stroke without an increase in the rates of overall major bleeding but with an increase of non-procedure-related bleeding.
A Systematic Review and Meta-analysis
TL;DR: A systematic review of studies published from January 1, 1950, through November 31, 2008 using PubMed, EMBASE, Web of Knowledge, CINAHL, and all Evidence-Based Medicine Reviews found that randomized clinical trials and prospective studies of RRTs that reported data on changes in the primary outcome of hospital mortality or the secondary outcome of cardiopulmonary arrest cases were included.
Journal ArticleDOI
Genetic Structure of Human Populations
Noah A. Rosenberg,Jonathan K. Pritchard,James L. Weber,Howard M. Cann,Kenneth K. Kidd,Lev A. Zhivotovsky,Marcus W. Feldman +6 more
TL;DR: General agreement of genetic and predefined populations suggests that self-reported ancestry can facilitate assessments of epidemiological risks but does not obviate the need to use genetic information in genetic association studies.
Related Papers (5)
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
Jessica L. Mega,Tabassome Simon,Jean-Philippe Collet,Jeffrey L. Anderson,Elliott M. Antman,Kevin P. Bliden,Christopher P. Cannon,Nicolas Danchin,Betti Giusti,Paul A. Gurbel,Benjamin D. Horne,Jean Sebastian Hulot,Adnan Kastrati,Gilles Montalescot,Franz-Josef Neumann,Lei Shen,Dirk Sibbing,P. Gabriel Steg,Dietmar Trenk,Stephen D. Wiviott,Marc S. Sabatine +20 more